Cath lab managers are involved in quality assurance and outcomes evaluation. One area of focus is contrast-induced nephropathy (CIN). CIN is important because it is the third leading cause of hospital-associated renal insufficiency, and even when it is clinically reversible it is associated with increased hospitalization, cost, and mortality. Assessment of nonmodifiable risk factors, treatment of modifiable risk factors, and evaluation of laboratory biomarkers is essential as predictors of CIN and to long-term survival.
AbeM.KimurT.MorimotoT.FukukawaY.KitaT. (2009). Incidence of and risk factors for contrast-induced neprhropathy after cardiac catheterization in Japanese patients. Circulation, 73, 1518-1522.
2.
AminiM.SalarifarM.AmirbaiglooA.MasoudkabirF.EsfahaniF. (2009). N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: A randomized clinical trial. Trials, 10, 45.
3.
BiguoriC.ManganelliF.ScarpatoP.EliaP. P.GoliaB.RiviezzoG.. . . RicciardelliB. (2002). Acetylcysteine and contrast agent-associated nephrotoxicity. Journal of the American College of Cardiology, 40, 298-303.
4.
BrarS.ShenA. Y.JorgensenM. B.KotlewskiA.AharonianV. J.DesaiN.. . . BurchetteR. J. (2008). Sodium bicarbonate vs sodium chloride for prevention of contrast mediated nephropathy in patients undergoing coronary angiography: A randomized trial. Journal of the American Medical Association, 300, 1038-1046.
5.
BriguoriC. (2009). Selection of contrast media: Current status of understanding. Giornale Italiano di Cardiologia, 10, 79-87.
6.
BudhirajaP.ChenZ.PopovtzerM. (2009). Sodium bicarbonate versus normal saline for protection against contrast nephropathy. Renal Failure, 31, 118-123.
7.
DangasG.IakovouI.NikolskyE.AymongE. D.MintzG. S.KipshidzeN. N.. . . MehranR. (2005). Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. American Journal of Cardiology, 95, 13-19.
8.
HölscherB.HeitmeyerC.FobkerM.BreithardtG.SchaeferR. M.ReineckeH. (2008). Predictors for contrast media-induced nephropathy and long-term survival: Prospectively assessed data from the randomized controlled Dialysis-Verus-Diuresis (DVD) trial. Canadian Journal of Cardiology, 24, 845-850.
9.
IshibashiY.YamauchiM.MushaH.MikamiT.KawasakiK.MiyakiF. (2010). Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology, 61, 721-723.
10.
KatoK.SatoN.YamamotoT.IwasakiY. K.TanakaK.MizunoK. (2008). Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circulation Journal, 72, 1499-1505.
11.
MadsenT. E.PearsonR. R.MuhlesteinJ. B.LappéD. L.BairT. L.HorneB. D.AndersonJ. L. (2009). Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography. Critical Pathways in Cardiology, 8, 167-171.
12.
MalyszkoJ.Bachorzewska-GajewskaH.PoniatowskiB.MalyszkoJ. S.DobrzyckiS. (2009). Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Renal Failure, 31, 910-919.
13.
MehranR.AymongE. D.NikolskyE.LasicZ.IakovouI.FahyM.. . . DangasG. (2004). A simple risk score for prediction of contrast-induced nepropathy after percutaneous coronary intervention. Journal of the American College of Cardiology, 44, 1393-1399.
14.
MehranR.NokolskyE. (2006). Contrast-induced neprhropathy: Definition, epidemiology, and patients at risk. Kidney International, 69, S11-S15.
15.
NunagM.BroganM.GarrickR. (2009). Mitigating contrast-induced acute kidney injury associated with cardiac catheterization. Cardiology in Review, 17, 263-269.
16.
PattiG.NuscaA.ChelloM.PasceriV.D’AmbrosioA.VetrovecG. W.Di SciascioG. (2008). Usefulness of stain pretreatment to prevent contrast-induced nephropathy and to improve long-term outcomes in patients undergoing percutaneous coronary interventions. American Journal of Cardiology, 101, 279-285.
17.
RihalC. S.TextorS. C.GrillD. E.BergerP. B.TingH. H.BestP. J.. . . HolmesD. R.Jr. (2002). Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation, 105, 2259-2264.
18.
RudnickM. R.DavidsonC.LaskeyW.StaffordJ. L.SherwinP. F. (2008). Iodixanol versus ioversol in patients with chronic kidney disease: The Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) trial. American Heart Journal, 156, 776-782.
19.
SenthilnathanS.GauvreauK.MarshallA. C.LockJ. E.BergersenL. (2009). Contrast administration in pediatric cardiac catheterization: dose and adverse events. Catheterization and Cardiovascular Interventions, 73, 814-820.
20.
TepelM.van der GietM.SchwarzfeldC.LauferU.LiermannD.ZidekW. (2000). Prevention of radiographic-contrast-agent-induced reduction in renal function by acetylcysteine. New England Journal of Medicine, 343, 180-184.
21.
WorasuwannarakS.PornratanarangsiS. (2010). Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization of PCI: Role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio. Journal of the Medical Association of Thailand, 93, S29-S34.
